B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Monday, setting a price target of $138, which is approximately 218.12% above the present share price of $43.38.
Mamtani expects Arcturus Therapeutics to post earnings per share (EPS) of -$0.92 for the first quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Moderate Buy rating of shares in Arcturus Therapeutics, with an average price target of $94.38.
The analysts price targets range from a high of $140 to a low of $46.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.33 million and a net profit of -$20.94 million. The company's market cap is $1.06 billion.
According to TipRanks.com, B.Riley Financial analyst Mayank Mamtani is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 29.4% and a 48.77% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.